INmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Average Target Price from Analysts

Key Points

• INmune Bio, Inc. (NASDAQ:INMB) has received a consensus recommendation of "Moderate Buy" from seven ratings firms, with an average price target of $18.40.
• The stock's 1-year performance shows a low of $1.89 and a high of $11.64, currently trading at around $2.71.
• Recent analyst reports have seen price targets significantly revised, with Maxim Group lowering their estimate from $30.00 to $8.00, while other firms have adjusted their ratings to "hold" or "underperform."

Shares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $18.40.

Several research analysts have recently commented on INMB shares. Maxim Group lowered their target price on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. Raymond James Financial cut shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a report on Monday, June 30th. BTIG Research reaffirmed a "neutral" rating on shares of INmune Bio in a report on Tuesday, July 1st. Finally, Scotiabank reaffirmed a "sector underperform" rating on shares of INmune Bio in a report on Tuesday, July 1st.

Institutional Trading of INmune Bio

A number of institutional investors have recently bought and sold shares of INMB. Quarry LP acquired a new stake in shares of INmune Bio in the 1st quarter worth about $48,000. Wells Fargo & Company MN raised its holdings in shares of INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after acquiring an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new stake in shares of INmune Bio in the 4th quarter worth about $48,000. JPMorgan Chase & Co. raised its holdings in shares of INmune Bio by 93.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock worth $53,000 after acquiring an additional 5,461 shares during the last quarter. Finally, PFG Investments LLC acquired a new stake in shares of INmune Bio in the 2nd quarter worth about $27,000. Institutional investors own 12.72% of the company's stock.

INmune Bio Price Performance

INmune Bio stock traded down $0.08 during trading hours on Friday, hitting $2.84. The company had a trading volume of 1,176,281 shares, compared to its average volume of 1,454,786. The firm has a market cap of $66.86 million, a PE ratio of -1.47 and a beta of 1.34. INmune Bio has a one year low of $1.89 and a one year high of $11.64. The firm has a 50-day moving average of $5.23 and a 200 day moving average of $6.99.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). The company had revenue of $0.05 million during the quarter. As a group, research analysts expect that INmune Bio will post -2.24 earnings per share for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.